Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Gross Margin (2019 - 2021)

VYNE Therapeutics (VYNE) has disclosed Gross Margin for 3 consecutive years, with 230.77% as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Gross Margin fell 31831.0% year-over-year to 230.77%, compared with a TTM value of 259.61% through Dec 2021, down 35298.0%, and an annual FY2021 reading of 259.61%, down 35298.0% over the prior year.
  • Gross Margin was 230.77% for Q4 2021 at VYNE Therapeutics, up from 688.72% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q4 2019 and bottomed at 688.72% in Q3 2021.
  • Average Gross Margin over 3 years is 87.94%, with a median of 84.51% recorded in 2020.
  • The sharpest move saw Gross Margin tumbled -1246bps in 2020, then tumbled -77737bps in 2021.
  • Year by year, Gross Margin stood at 100.0% in 2019, then dropped by -12bps to 87.54% in 2020, then crashed by -364bps to 230.77% in 2021.
  • Business Quant data shows Gross Margin for VYNE at 230.77% in Q4 2021, 688.72% in Q3 2021, and 169.49% in Q2 2021.